Fabry Disease Registry & Pregnancy Sub-registry

 Fabry Disease / Posted 1 year ago

Brief Summary

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient’s treating physician.

The primary objectives of the Registry are:

  • To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease;
  • To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care;
  • To characterize and describe the Fabry population as a whole;
  • To evaluate the long-term safety and effectiveness of Fabrazyme®

Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient’s physician. If a patient consents to this Sub-registry, information about the patient’s medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.

  • Inclusion Criteria :
    • Ages Eligible for Study: Child, Adult, Older Adult
    • Sexes Eligible for Study: All
    • Accepts Healthy Volunteers: No
    • All patients with a confirmed diagnosis of Fabry disease are eligible for inclusion in the Registry.
    • For Fabry Pregnancy Sub-registry: It is recommended that pregnancy data be collected on eligible women regardless of infant enrollment. In the event of patients having multiple pregnancies, data collection for each individual pregnancy is encouraged for all women enrolled in this Sub-Registry.
    • Fabry Registry: All patients with a confirmed diagnosis of Fabry disease who have signed the informed consent and patient authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as a documented deficiency in plasma or leukocyte αGAL (alpha-galactosidase) enzyme activity and/or mutation(s) in the gene coding for αGAL. Fabry Pregnancy Sub-registry:
    • Eligible women must:
    • be enrolled in the Fabry Registry.
    • be pregnant, or have been pregnant with appropriate medical documentation available.
    • provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.
  • Exclusion Criteria :
    • There are no exclusion criteria
  • Study start date : July 31, 2001
  • Study end date : January 31, 2034
  • Wales-Based Study Contact : Please speak to your clinician
  • Principal Investigator : Genzyme, a Sanofi Company
Contact details

Royal Free Hospital, LondonLondon,England,NW3 2QG  Show Phone Number Contact-Us@sanofi.com

No post found